Table 2.
Active clinical trials investigating immunotherapy-based treatments in HNSCC.
| Trial ID | Phase | Investigational Therapies | Study Population | Status |
|---|---|---|---|---|
| NCT04754321 | I | Pembrolizumab + Salvage Surgery + RT | Recurrent or Persistent | Recruiting |
| NCT05222932 | I | TILT-123 and Avelumab | R/M | Recruiting |
| NCT05635643 | I | CHS-114 | R/M | Recruiting |
| NCT02988960 | I | ABBV-927 +/− ABBV-181 | LA; R/M | Not Recruiting |
| NCT04999202 | I | BAY2416964 + Pembrolizumab | R/M | Not Recruiting |
| NCT03283605 | I/II | Durvalumab + Tremelimumab + SBRT | Metastatic | Not Recruiting |
| NCT03317327 | I/II | Nivolumab + RT | Recurrent or 2nd Primary | Recruiting |
| NCT04555837 | I/II | Alisertib + Pembrolizumab | R/M; HPV+ | Not Recruiting |
| NCT06319963 | I/II | Lenti-HPV-07 | R/M | Not Yet Recruiting |
| NCT04815720 | I/II | Pepinemab + Pembrolizumab | LA; R/M | Recruiting |
| NCT04977453 | I/II | GI-101 | Metastatic | Recruiting |
| NCT05597839 | I/II | DF9001 | R/M | Recruiting |
| NCT04198766 | I/II | INBRX-106 +/− Pembrolizumab | LA; Metastatic | Recruiting |
| NCT05086692 | I/II | MDNA11 + Pembrolizumab | LA; Metastatic | Recruiting |
| NCT05592626 | I/II | STAR0602 | LA; R/M | Recruiting |
| NCT06170697 | II | Camrelizumab + CT + RT | R/M; Short-Term Post-Op Progression | Recruiting |
| NCT03546582 | II | RT +/− Pembrolizumab | Recurrent or 2nd Primary | Recruiting |
| NCT04326257 | II | Nivolumab + (Relatlimab or Ipillimumab) | R/M | Not Recruiting |
| NCT03341936 | II | Nivolumab + Lirilumab + Salvage Surgery | Recurrent | Not Recruiting |
| NCT06239220 | II | PD-L1 t-haNK + N-803 + Cetuximab | LA; R/M | Recruiting |
| NCT04428151 | II | Lenvatinib + Pembrolizumab | R/M | Recruiting |
| NCT06062420 | II | Dostarlimab +/− Other Immunotherapies | R/M | Recruiting |
| NCT03993353 | II | Pembrolizumab + Tadalafil | R/M | Recruiting |
| NCT04260126 | II | PDS0101 + Pembrolizumab | R/M; HPV+ | Not Recruiting |
| NCT06052839 | II | Pembrolizumab + CT | R/M | Recruiting |
| NCT05260671 | II | Penpulimab + Cetuximab | R/M | Recruiting |
| NCT03946358 | II | Atezolizumab and UCPVax | LA; Metastatic; HPV+ | Not Recruiting |
| NCT03228667 | II | N-803 + (Pembrolizumab or Nivolumab) | R/M | Not Recruiting |
| NCT05686226 | II | E7 TCR-T cells | R/M; HPV+ | Recruiting |
| NCT04802876 | II | Spartalizumab or Tislelizumab | R/M | Recruiting |
| NCT04357873 | II | Pembrolizumab + Vorinostat | R/M | Not Recruiting |
| NCT06295731 | II/III | Pembrolizumab +/− INBRX-106 | R/M | Recruiting |
| NCT06513884 | II/III | HB-202/HB-201 + Pembrolizumab | R/M Oral SCC; HPV+ | Not Yet Recruiting |
Abbreviations: R/M: recurrent/metastatic; LA: locally advanced; RT: radiation therapy; SBRT: stereotactic body radiation therapy; HPV: human papillomavirus.